Published by Coherent Market Insights
Posted on September 20, 2021
Transcatheter aortic valve implantation (TAVI), also referred as transcatheter aortic valve replacement, or percutaneous valve replacement is a minimally invasive procedure that repairs the functionality of the old and damaged valve. The aortic valve allows the blood flow from the ventricle to the rest of the body. A malfunction in the opening and closing of this valve leads to aortic stenosis. The patients suffering from aortic stenosis suffer from extra strain on the heart, which causes swelling in the ankles, breathlessness, dizziness, chest pain, and frequent black outs.
The transcatheter aortic valve implantation is a procedure that allows replacement of the aortic valve by implantation of a catheter. Catheter is a long narrow tube that is inserted in the blood vessel by making a small incision in the chest. The transcatheter aortic valves are made from natural tissues of either a pig or a cow. This natural tissue isolated from the heart of a pig or cow is then re-engineered and reprocessed by attaching the valve to a flexible and expandable mesh frame. Once the new valve is implanted, the catheter is removed and the valve starts functioning normally.
>>> Get | Request Sample Report @
https://www.coherentmarketinsights.com/insight/request-sample/918
To Learn More:
According to the Virtual Medical Centre (VMC) 2017, one in every four people suffer from congenital valvular disease that may lead to the development of Aortic stenosis at a young age. Additionally, people aged 65 years and above are more likely to have degenerative aortic stenosis due to calcification of the aortic valve or atherosclerosis. Moreover, the American Heart Association statistics of 2017, states that around 2200 deaths are experienced in the U.S. due to cardiovascular diseases each day, accounting for 1 death every 40 seconds. .The same report also suggests that the coronary heart disease is the leading cause of death in the U.S. accounting for 45.1% of deaths in the country. The rise in prevalence of cardiovascular diseases and aortic stenosis provides immense opportunities for key players to expand products and increase sales over the forecast period.
Several novel TAVI devices that are in the last phases of the clinical trials. For instance, in 2016, the SAPIEN XT by the Edward Lifesciences has been FDA-approved and is now in the clinical phase trial serving patients with intermediate risk. This serves as one of the prime reasons for growth of the global transcatheter aortic valve implants market. Moreover, the success rate of the TAVI surgeries coupled with shorter recovery time also help drive the global transcatheter aortic implantation market growth. Apart from this, the high prevalence rates of aortic stenosis and coronary artery diseases in the geriatric population and younger population contributes to growth of the global transcatheter aortic implantation market. An article by National Centre for Biotechnology Information (NCBI) stated that aortic stenosis exists in 2%-9% of the population aged above 65 years. The number of centers providing the TAVI surgical process is gradually increasing, thereby creating a wide scope for key players to expand their distribution channels. According to the Edward Lifesciences, the TAVR procedure was available at more than 400 centers in the U.S., in 2015. However, stringent regulatory procedures for approval of new products that are also time consuming, are restraining the growth of the global transcatheter aortic valve implantation market.
The key players operating in the global transcatheter aortic valve implantation market include Edwards Lifesciences, Boston Scientific Corporartion, Jenavalve Technology, Inc., HLT, Inc., Meril Life Sciences Pvt. Ltd., Medtronic Plc., St. Jude Medical, Inc., Transcatheter Technologies GmbH, and SYMETIS SA
Detailed Segmentation
On the basis of procedure, the global transcatheter aortic valve implantation market is segmented into:
On the basis of end user, the global transcatheter aortic valve implantation market is segmented into:
Transcatheter Aortic Valve Implantation (TAVI) Market by Geography Analysis::
North America (The US, Canada, and Mexico)
Europe (the UK, Germany, France, and Rest of Europe)
Asia Pacific (China, India, and Rest of Asia Pacific)
Latin America (Brazil and Rest of Latin America)
Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)
Key Players In Transcatheter Aortic Valve Implantation (TAVI) Market
The “Global Transcatheter Aortic Valve Implantation (TAVI) Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Direct Flow Medical Inc., Edwards Lifesciences, Boston Scientific Corporartion, Jenavalve Technology, Inc., HLT, Inc., Meril Life Sciences Pvt. Ltd., Medtronic Plc., St. Jude Medical, Inc., Transcatheter Technologies GmbH, and SYMETIS SA.
Reasons to Purchase this Report
Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post sales analyst support
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/918
What is Transcatheter Aortic Valve Implantation (TAVI) Market?
What are the key driving factors for the growth of Transcatheter Aortic Valve Implantation (TAVI) Market?
What are the top players operative in Transcatheter Aortic Valve Implantation (TAVI) Market?
What segments are covered in Transcatheter Aortic Valve Implantation (TAVI) report?
How can I get sample report/company profiles of Transcatheter Aortic Valve Implantation (TAVI) Market?
In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Transcatheter Aortic Valve Implantation (TAVI) Market to Clinical Trial Success of the FDA approved appeared first on Gatorledger.
Transcatheter aortic valve implantation (TAVI), also referred as transcatheter aortic valve replacement, or percutaneous valve replacement is a minimally invasive procedure that repairs the functionality of the old and damaged valve. The aortic valve allows the blood flow from the ventricle to the rest of the body. A malfunction in the opening and closing of this valve leads to aortic stenosis. The patients suffering from aortic stenosis suffer from extra strain on the heart, which causes swelling in the ankles, breathlessness, dizziness, chest pain, and frequent black outs.
The transcatheter aortic valve implantation is a procedure that allows replacement of the aortic valve by implantation of a catheter. Catheter is a long narrow tube that is inserted in the blood vessel by making a small incision in the chest. The transcatheter aortic valves are made from natural tissues of either a pig or a cow. This natural tissue isolated from the heart of a pig or cow is then re-engineered and reprocessed by attaching the valve to a flexible and expandable mesh frame. Once the new valve is implanted, the catheter is removed and the valve starts functioning normally.
>>> Get | Request Sample Report @
https://www.coherentmarketinsights.com/insight/request-sample/918
To Learn More:
According to the Virtual Medical Centre (VMC) 2017, one in every four people suffer from congenital valvular disease that may lead to the development of Aortic stenosis at a young age. Additionally, people aged 65 years and above are more likely to have degenerative aortic stenosis due to calcification of the aortic valve or atherosclerosis. Moreover, the American Heart Association statistics of 2017, states that around 2200 deaths are experienced in the U.S. due to cardiovascular diseases each day, accounting for 1 death every 40 seconds. .The same report also suggests that the coronary heart disease is the leading cause of death in the U.S. accounting for 45.1% of deaths in the country. The rise in prevalence of cardiovascular diseases and aortic stenosis provides immense opportunities for key players to expand products and increase sales over the forecast period.
Several novel TAVI devices that are in the last phases of the clinical trials. For instance, in 2016, the SAPIEN XT by the Edward Lifesciences has been FDA-approved and is now in the clinical phase trial serving patients with intermediate risk. This serves as one of the prime reasons for growth of the global transcatheter aortic valve implants market. Moreover, the success rate of the TAVI surgeries coupled with shorter recovery time also help drive the global transcatheter aortic implantation market growth. Apart from this, the high prevalence rates of aortic stenosis and coronary artery diseases in the geriatric population and younger population contributes to growth of the global transcatheter aortic implantation market. An article by National Centre for Biotechnology Information (NCBI) stated that aortic stenosis exists in 2%-9% of the population aged above 65 years. The number of centers providing the TAVI surgical process is gradually increasing, thereby creating a wide scope for key players to expand their distribution channels. According to the Edward Lifesciences, the TAVR procedure was available at more than 400 centers in the U.S., in 2015. However, stringent regulatory procedures for approval of new products that are also time consuming, are restraining the growth of the global transcatheter aortic valve implantation market.
The key players operating in the global transcatheter aortic valve implantation market include Edwards Lifesciences, Boston Scientific Corporartion, Jenavalve Technology, Inc., HLT, Inc., Meril Life Sciences Pvt. Ltd., Medtronic Plc., St. Jude Medical, Inc., Transcatheter Technologies GmbH, and SYMETIS SA
Detailed Segmentation
On the basis of procedure, the global transcatheter aortic valve implantation market is segmented into:
On the basis of end user, the global transcatheter aortic valve implantation market is segmented into:
Transcatheter Aortic Valve Implantation (TAVI) Market by Geography Analysis::
North America (The US, Canada, and Mexico)
Europe (the UK, Germany, France, and Rest of Europe)
Asia Pacific (China, India, and Rest of Asia Pacific)
Latin America (Brazil and Rest of Latin America)
Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)
Key Players In Transcatheter Aortic Valve Implantation (TAVI) Market
The “Global Transcatheter Aortic Valve Implantation (TAVI) Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Direct Flow Medical Inc., Edwards Lifesciences, Boston Scientific Corporartion, Jenavalve Technology, Inc., HLT, Inc., Meril Life Sciences Pvt. Ltd., Medtronic Plc., St. Jude Medical, Inc., Transcatheter Technologies GmbH, and SYMETIS SA.
Reasons to Purchase this Report
Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post sales analyst support
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/918
What is Transcatheter Aortic Valve Implantation (TAVI) Market?
What are the key driving factors for the growth of Transcatheter Aortic Valve Implantation (TAVI) Market?
What are the top players operative in Transcatheter Aortic Valve Implantation (TAVI) Market?
What segments are covered in Transcatheter Aortic Valve Implantation (TAVI) report?
How can I get sample report/company profiles of Transcatheter Aortic Valve Implantation (TAVI) Market?
In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Transcatheter Aortic Valve Implantation (TAVI) Market to Clinical Trial Success of the FDA approved appeared first on Gatorledger.
Explore more articles in the Research Reports category
